Dec. 2025 – New US patent further strengthens River Stone IP
River Stone Biotech have announced the grant of a new patent, Microbial Cell with Improved in vivo Conversion of Thebaine/Oripavine. This patent, covering the company’s uptake transporter technology, is the first grant of a new patent family and gives the company protection on its unique approach to bioconversion across a range of products. ...
Oct. 2025 – River Stone to attend CPHI 2025
River Stone will be attending CPHI in Frankfurt next week. RSB is dedicated to providing life changing APIs and formulations via innovative production methods that blend synthetic biology and chemistry processes. In the first instance RSB is pleased to be able to make a meaningful contribution to the important Opioid Dependence/Substance Abuse Prevention programs around the world. River Stone works with a small number of global providers to establish a virtual cross-functional operation to enable its API offering and is looking to strengthen its network of potential partners and customers. ...
Dec. 2023 – Advancing to global commercial launch
Cambridge, December 18, 2023 – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering, today announced the issuance of a U.S. Patent covering a key family of enzymes enabling preparation of precursors to high value compounds such as buprenorphine, naloxone, naltrexone, and nalmefene. These enzymes are key to enabling a process that is higher efficiency and uses more environmentally-friendly reagents than conventional production methods. This production approach works synergistically with RSB’s proprietary chemistry methods, as described in previously granted US 11,390,628 and AU 2018268173, to generate these high value APIs. U.S. Patent No. US 11,781,164 is entitled...
Jul. 2022 – River Stone Biotech Inc. Announces Issuance of U.S. Patent
River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the issuance of a U.S. Patent covering a unique production technology for the preparation of Buprenorphine. The process is higher efficiency and uses more environmentally-friendly reagents than conventional production methods. This production approach is synergistic with RSB’s proprietary methods to produce alkaloid starting materials via fermentation in a cost-effective manner, as described in previously granted US Patent 11,060,071. U.S. Patent No. 11,390,628 is entitled “Preparation of buprenorphine“ and is expected to provide RSB with protection until...
Apr. 2022 – River Stone Biotech Inc. participates in DCAT 2022
Cambridge, April 28, 2022. River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the use of its transformational technology in the manufacture of buprenorphine and other n-demethylation products including naloxone and naltrexone. The novel patent-protected technology employed will allow reliable supply of these vital APIs at much superior value – both economically and environmentally – to those available in the market today. The technology employs a combination of state-of-the-art synthetic biology followed by other more traditional production methods; this novel approach eliminates the high...
Nov. 2021 – River Stone Biotech Inc. Announces $6.8M Series B Financing
Cambridge, Nov. 10, 2021 River Stone Biotech Inc. Announces $6.8M Series B Financing to Advance Lead Pipeline Projects To Treat Opiate Use Disorder and Opiate Overdose. – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering and operating within the contract development and manufacturing (CDMO) space, today announced the completion of a $6.8 million Series B financing. Led by an individual specialty healthcare investor, the financing included new investments from 5 private investors along with further participation from existing investor, Dick Cashin. In conjunction with the financing, James (Jeb) Besser, has been appointed to River Stone’s board of directors. Proceeds...